Clinical Trials Logo

Gastroesophageal Reflux clinical trials

View clinical trials related to Gastroesophageal Reflux.

Filter by:

NCT ID: NCT04118647 Recruiting - Clinical trials for Gastroesophageal Reflux Disorder

Effective Mechanisms of Wu-Chu-Yu Tang on Gastroesophageal Disorder

Start date: October 2019
Phase: Phase 4
Study type: Interventional

Gastroesophageal reflux disorder (GERD) is due to gastric content reflux to esophagus cause symptom and complication including intra-esophagus such as reflux esophagitis, and extra-esophagus such as cough etc. Because the changes of dietary habit, and improvement of examination skill and data analysis, the prevalence of GERD increased 2.5 multiple from 1995 to 2002, and suggesting the prevalence is 25% in Taiwan community. The etiology of GERD is multi-effect, such as transient lower esophageal sphincter relaxation and abnormal pressure of lower esophageal sphincter, which may induced the esophageal mucosal injury by gastric acid, bile or pancreases enzyme. Wu-Chu-Yu tang consists of Evodia fargesii Dode (Evodia Fruit), Panax ginseng C. (Ginseng), Ziziphus jujube Mill (Chinses Date), Zingiber officinale Rosee (Fresh Ginger).According to "I-Fang-Chi-Chieh" and "Shanghonzobinglun" recordings that Wu-Chu-Yu tang can treat vomiting, and also can relax gastric tonicity and can enhance peristalsis of stomach. According to Randomized, double blind, placebo control trial to evaluate the efficacy of Wu-Chu-Yu Tang on gastroesophageal reflux disease, we know the Wu-Chu-Yu tang have the equivalent effect proton pump inhibitor omeprazole. But, the mechanism of Wu-Chu-Yu tang is still unknown.

NCT ID: NCT04105894 Not yet recruiting - Clinical trials for Gastro Esophageal Reflux

Gastric Reflux and Sinonasal Symptoms

Start date: January 2020
Phase:
Study type: Observational

The study is conducted to: - study correlation between sinonasal troubles & GERD - Assess whether antireflux therapy improve state of sinus in patients complaining from reflux & sinonasal symptoms

NCT ID: NCT04094402 Recruiting - Clinical trials for Gastroesophageal Reflux Disease

Epi-GERD Study: Epidemiological Evaluation in Patients With Gastro-Esophageal Reflux Disease (GERD)

Epi-ERGE
Start date: June 4, 2019
Phase:
Study type: Observational

Cross-sectional epidemiological study in patients with diagnosis of GERD (Gastroesophageal Reflux Disease) and with current treatment or with a history of recent treatment with some PPI (Proton Pump Inhibitor), in order to evaluate the persistence and / or relapse of symptoms of GERD.

NCT ID: NCT04085211 Recruiting - Clinical trials for Inflammatory Bowel Diseases

Image-Enhanced Endoscopy in the Gastrointestinal Tract

Start date: July 1, 2019
Phase:
Study type: Observational

This study evaluates a range of endoscopic image enhancement techniques for assessing conditions involving the gastrointestinal tract. This study aims to determine: (i) the accuracy of different techniques to diagnose or grade severity of several gastrointestinal conditions (ii) if image-enhancement techniques could potentially replace investigations currently used in daily practice (e.g. biopsy) with a view to reduce costs and shorten the interval to initiate treatment

NCT ID: NCT04080726 Completed - Clinical trials for Erosive Gastroesophageal Reflux Disease

Efficacy and Safety of HIP1601 Capsule

Start date: October 25, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study is to investigate the safety and clinical efficacy of HIP1601 in patients with erosive gastroesphageal reflux disease.

NCT ID: NCT04065516 Enrolling by invitation - Clinical trials for Gastroesophageal Reflux

ARAT for Reflux Disease After Peroral Endoscopic Myotomy in Patients With Achalasia

ARAT
Start date: July 3, 2019
Phase: N/A
Study type: Interventional

The peroral endoscopic myotomy for the treatment of achalasia is associated with a higher incidence of gastroesophageal reflux disease compared with Heller's myotomy. Remodeling of the esophagogastric junction with hybrid argon plasma could decrease the passage of gastric or gastroduodenal content into the esophagus.

NCT ID: NCT04052581 Withdrawn - Clinical trials for Gastroesophageal Reflux Disease

Prospective Collection of Outcome Data Post POEM-TIF Procedure

Start date: July 2023
Phase:
Study type: Observational

Per Oral Endoscopic Myotomy has been established as a safe and effective treatment of Achalasia type I and II; however, it is limited by post-procedure gastroesophageal reflux. Transoral Incisionless Fundoplication (TIF) has been introduced as the endoscopic gold standard for anti-reflux procedure. Recently, combined POEM-TIF has been performed successfully as a standard of care treatment for patients with severe GER after POEM. We aim to study the safety and feasibility of performing POEM-TIF (POEM and TIF in the same endoscopic session). This study will also put the groundwork for a randomized clinical trial to further study the clinical outcome of the POEM-TIF procedure.

NCT ID: NCT04036942 Recruiting - Clinical trials for Gastroesophageal Reflux Disease

Antireflux Ablation Therapy (ARAT) Vs Antireflux Mucosectomy (ARMS) In The Management Of Gastroesophageal Reflux Disease

Start date: July 15, 2019
Phase: N/A
Study type: Interventional

Gastroesophageal reflux disease has a high global prevalence, proton pump inhibitors are the cornerstone in the management but 10-20% of the patients are refractory to these, surgical treatment being an option of treatment in these patient but its associated with high morbidity, as well as a greater possibility of early therapeutic failure, for these reasons new therapies are in development being the mucosectomy with band and ablation of the esophagogastric junction with hybrid argon plasma options widely available that can offer a viable therapeutic option for patients with difficult control of symptoms or those who does not want to receive continuous medical treatment or surgical treatment. The aims of the study is to evaluate the safety and efficacy of this new techniques in the management or gastroesophageal reflux disease without hiatal hernia.

NCT ID: NCT04034017 Completed - Clinical trials for Gastroesophageal Reflux

Gastroesophageal Reflux Disease Among College Students

Start date: September 1, 2018
Phase:
Study type: Observational

Background: Gastroesophageal reflux disease (GERD) is a worldwide prevalent gastrointestinal disorder which has negative impacts on quality of life, health and economy. The aims of this study were to assess the prevalence of GERD among college students in southwestern Saudi Arabia and to evaluate its personal, academic and stress correlates Materials and Methods: Through a cross-sectional study design, a self-reported questionnaire was distributed between a representative sample of students in health and non-health care colleges in southwestern Saudi Arabia. The questionnaire included data for personal characteristics, academic study, and Arabic versions of GERD questionnaire (GerdQ) and Cohen's Perceived Stress Scale.

NCT ID: NCT04028466 Terminated - GERD Clinical Trials

Effectiveness of Vonoprazan vs Omeprazole as Empiric Therapy for Gastroesophageal Reflux Disease (GERD) Patients Without Alarm Features

Start date: May 26, 2019
Phase: Phase 4
Study type: Interventional

Gastroesophageal reflux disease is a commonly encountered disorder in daily practice. Proton pump inhibitor therapy has been the cornerstone of treatment for decades. Although it has been proven to be highly effective, there is still room for improvement. A local study showed that only 57.3% of subjects are asymptomatic after 4 weeks treatment with rabeprazole. Recently a new drug was developed with better absorption, higher bioavailability, more sustained increased pH in the stomach and more targeted action to the H-K ATPase pump. Vonoprazan, belongs to a new class of acid suppressant medications, the potassium-competitive acid blocker (P-CAB). Vonoprazan has been studied and used successfully in Japan for H pylori eradication therapy, GERD, gastric and duodenal ulcers with favorable safety profile. However, to the author's knowledge, no study yet exists comparing vonoprazan to a proton pump inhibitor in the treatment of GERD outside Japan. This study aims to determine whether vonoprazan is superior to omeprazole in relieving symptoms in treatment-naïve adult patients with GERD.